| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11382922 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Jul, 2040
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857161 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(5 years from now) | |
| US8334279 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κB for treatment of disease |
May, 2029
(5 years from now) | |
| US11833159 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(5 years from now) | |
| US11690853 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
Mar, 2033
(8 years from now) | |
| US11471471 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(15 years from now) | |
Agamree is owned by Catalyst Pharms.
Agamree contains Vamorolone.
Agamree has a total of 6 drug patents out of which 0 drug patents have expired.
Agamree was authorised for market use on 26 October, 2023.
Agamree is available in suspension;oral dosage forms.
Agamree can be used as treatment of duchenne muscular dystrophy.
Drug patent challenges can be filed against Agamree from 27 October, 2027.
The generics of Agamree are possible to be released after 16 July, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Treatment: Treatment of duchenne muscular dystrophy
Dosage: SUSPENSION;ORAL
AGAMREE family patents
